



JAGSONPAL PHARMACEUTICALS LIMITED

Regd. Office. T-210 J, Shahpur Jat, New Delhi - 110 049 (INDIA)
Fax 0091-11-26498341, 26494708, Phone : 0091-11-46181100, 46109900
Email: nandita.singh@jagsonpal.com; cs@jagsonpal.com
CIN No. L74899DL1978PLC009181

Date: April 30th, 2022

To,
The Department of Corporate Services-
Listing
BSE Ltd,
Phiroze Jeejeebhoy Towers,
Dalai Street
Mumbai-400 001

Scrip Code: 507789

To,
The Department of Corporate Services-
Listing
National Stock Exchange of India Ltd
Exchange Plaza, C-1, Block G,
Bandra Kuria Complex,
Bandra (E)
Mumbai — 400 051
Symbol: JAGSNPHARM

Sub: Initial Disclosure to be made by an entity under SEBI circular on Fund raising by issuance of Debt Securities by Large Entities

Ref: SEBI Circular No.- SEBI/HO/DDHS/CIR/P/2018/144 dated November 28, 2018

Dear Sir/ Madam

Pursuant to Para 4.1 (i) of the SEBI circular Fund raising by issuance of Debt Securities by Large Entities, we confirm that Jagsonpal Pharmaceuticals Limited does not fall under category of Large Corporate as per the applicability criteria given under the SEBI circular as referred above for the financial year 2021- 22.

You are requested to take the above information on record.

For JAGSONPAL PHARMACEUTICALS LIMITED

Nandita Singh
Company Secretary and Compliance Officer